Clinical Trial Update: A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 study investigates an implantable iontophoresis device delivering gemcitabine once weekly or twice weekly for non-resectable pancrea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: Continuity Biosciences, LLC | Conditions: Pancreatic Adenocarcinoma Non-resectable | Phase 1 | Status: RECRUITING